Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0001209191-20-060584

Chief R&D Officer sold 16,380 shares at $16.40 ($268,632)

From the SEC's structured data for this filing

Trades in this filing

Zalevsky Jonathan · Chief R&D Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2020-11-23 Sale : show line 1 in the form −16,380 $16.40 $268,632 250,317 D
Open-market sales · 16,380 sh · avg $16.40 · $268,632
Loading xslF345X03/doc4.xml…